According to a recently published report by Future Market Insights (FMI), the global unstable angina therapeutics market is poised for significant growth, projected to reach US$ 6.6 billion by 2033, with a compound annual growth rate (CAGR) of 5% from 2023 to 2033. The market, which was valued at US$ 4.05 billion in FY 2023, is being primarily driven by an increase in the number of individuals being treated for unstable angina and the adoption of new therapeutics with enhanced safety and efficacy.
Unstable angina, a condition affecting approximately 200,000 Americans annually according to a study conducted by the Cleveland Clinic, is more prevalent among older individuals, men, and those with lifestyle factors such as smoking, high blood sugar levels, or elevated blood pressure.
Request A Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16605
“The rising prevalence of unstable angina underscores the importance of continuous innovation in therapeutics,” stated a spokesperson from Future Market Insights. “New advancements such as Rivaroxaban, varespladib, and otamixaban, currently in late phases of clinical development, hold promise for improving patient outcomes.”
Leading manufacturers in the market include Bayer Healthcare, Sanofi, Anthera Pharmaceuticals, and Ablynx. Renowned specialists in the industry are implementing various therapeutic and combat initiatives, ranging from pipeline research to collaboration with medical technology companies, to advance therapeutics infrastructure.
Furthermore, the increasing number of pharmaceuticals approved by regulatory agencies is expected to further propel market expansion. Clopidogrel, FDA-approved for the medical treatment of unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI), has demonstrated efficacy in reducing the risk of adverse cardiovascular events when combined with aspirin.
As the demand for effective therapies for unstable angina continues to rise, stakeholders in the healthcare sector are encouraged to invest in research and development efforts aimed at addressing unmet medical needs and improving patient outcomes.
Key Takeaways from the Market Study:
- The market for Unstable Angina Therapeutics is expected to grow to US$ 4.05 billion in FY 2023.
- According to Future Market Insights, the Unstable Angina Therapeutics market grew at a CAGR of 4% from 2018 to 2022.
- In the United States, the occurrence of unstable angina is increasing, with nearly 1 million hospitalized patients receiving a primary diagnosis of unstable angina each year.
- In 2022, North America held 45% of the market share for unstable angina therapeutics
- Europe to be the 2nd largest market for unstable angina therapeutics
- Beta-blockers to be the most widely used drug, expected to register a CAGR of 4.4%
“The presence of benefits such as improved healthcare, lower surgical costs, and superior hospitality are among the significant indicators predicted to propel the market in advanced economies over the forecast period.” says FMI’s analyst.
Request Report Methodology: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16605
Key Market Players:
Bayer Healthcare, Sanofi, Anthera Pharmaceuticals, Ablynx, Saphnix Life Sciences, Copperhead Chemical, Medtronic, Enomark Kinetics, and CDH Fine Chemical are key players in the Unstable Angina Therapeutics market. Some of the recent developments are listed below.
- Bayer Healthcare has introduced aspirin, which is recommended to patients with an initial MI or unstable angina pectoris to decrease the combined risk of death and previous MI or unstable angina pectoris.
- The FDA approved Praluent® (alirocumab) in April 2019 to prevent heart attacks, strokes, and unstable angina that necessitates hospitalization. Praluent treatment was found to be beneficial in patients who were already receiving other lipid-lowering treatments, such as adequate statins.
Key Segments Profiled in the Unstable Angina Therapeutics Industry Survey:
By Treatment:
- Percutaneous Coronary Intervention (PCI)
- Coronary Artery Bypass Graft Surgery
- Supplemental Oxygen Therapy
- Drug Class
- NSAIDs
- Vasodilators
- Platelet Aggregation Inhibitors
- Anticoagulants
- Beta-blockers
By End User:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Get a Purchase on the Report: https://www.futuremarketinsights.com/checkout/16605
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
